

Do proposed definitions meet the unmet needs of cardiologists and cardiac surgeons?

Orphan devices and unmet medical needs

Patrick Myers, MD, FEBCTS, FESC

ESC Cardiovascular Round Table - 18 April 2024



Disclosures

- Financial: none
- Intellectual:
 - Surgeon
 - EACTS Secretary General
 - Board member and former secretary, EBCTS
 - President, CTSNet
 - International Director, STS
 - Advisor to early-stage MedTech startups (NeuroSoft, Hi-D imaging, Artiria, Aspivix)



Orphan medical devices regulations globally



CLIN^{R+}

Orphan Criteria	Australia	Brazil	Europe	Japan	USA
Regulatory Framework	Drugs only	Drugs only	Drugs only	Yes	Yes
Prevalence / Incidence of rare disease	Prevalence: 50/100k Incidence: NA	Prevalence: 65/100k Incidence: NA	Prevalence: 50/100k Incidence: NA	Prevalence: 40/100k Incidence: NA	Prevalence: 60/100 Incidence: 8000 per/year
Indication	Serious medical condition (single)	Serious debilitating condition	Life-threatening or chronically debilitating condition	Serious diseases, (incl. difficult to treat diseases)	NA
Alternatives	None or Significant benefit to patient care vs alternatives	NA	None or significant benefit to patients	None or high effectiveness/safety vs alternatives	NA
Overseas Approval	Not previously refused for approval for safety	NA	NA	Sufficient clinical data or explanation of theoretical rationale for use in the target disease	NA
Performance	.NA.:	Propose to significantly modify evolution or enable remission of disease	NA	NA	Exempt from effectiveness evaluation

Conundrum of Medical Device Regulation







Rare diseases







rare diseases have been identified, with more being discovered every day.¹



Although the diseases themselves are rare. rare diseases affect 350 million people worldwide.1.2



>80% of rare diseases are caused by faulty genes, underscoring the need for effective treatment rather than preventive measures.^{2,3} 5%

Only 5% of rare diseases have treatments, high need for innovative therapies.²

Did you know?



If all the people with a rare disease lived in one country, it would be the world's 3rd populous country.

50% of the people affected are children.1

Individually rare. collectively common.

While each disease affects few people, collectively many lives are touched.



Definitions



Orphan medical devices

 Medical devices that benefit a relatively <u>small group of patients</u> in the treatment or diagnosis of a disease or condition

> * Annex to the COMMISSION IMPLEMENTING DECISION on the financing of the Programme for the Union's action in the field of health ('EU4Health Programme') and the adoption of the work programme for 2023

• Lack alternatives

Orphan disease

• Disease occurring in <1 in 2'000 people

EUROPEAN MEDICINES AGENCY

EMA definition

Orphan medical devices



- Opportunity & resources cost to stakeholders (small addressable market)
- Unfavorable development & investigation cost : ROI ratio
- No published definitions by EU Medical Devices Coordination Group (MDCG)!

Orphan medicine definition



- Treatment, prevention or diagnosis of a disease that is lifethreatening or chronically debilitating
- Prevalence in EU ≤5 in 10'000 or sufficient ROI unlikely
- No satisfactory method of diagnosis, prevention or treatment of the condition concerned can be authorized
- Or, if such a method exists, the medicine must be of significant benefit to those affected by the condition

Regulation (EC) 141/2000

Orphan medicine definition

- Benefits
 - Protocol assistance
 - Market exclusivity once the medicine is on the market
 - Fee reductions depending on the status of the sponsor and the type of service required
 - Global partnerships
 - US FDA
 - Japanese Ministry of Health, Labour and Welfare
- 60% intended for pediatric use!

Regulation (EC) 141/2000

Path forward for Orphan medical devices

- Business models with incentives needed to bring these devices to the market
 - Supportive frameworks
 - Avoid withdrawal for financial reasons
 - Regulate off-label use
 - Manage materiovigilance



Solutions





European Commission

European Health Union: Helping the transition to the new rules on medical devices and *in vitro* diagnostics

Solutions





Orphan medical devices regulations globally





CLIN^{R+}

Orphan Criteria	Australia	Brazil	Europe	Japan	USA
Regulatory Framework	Drugs only	Drugs only	Drugs only	Yes	Yes
Prevalence / Incidence of rare disease	Prevalence: 50/100k Incidence: NA	Prevalence: 65/100k Incidence: NA	Prevalence: 50/100k Incidence: NA	Prevalence: 40/100k Incidence: NA	Prevalence: 60/100 Incidence: 8000 per/year
Indication	Serious medical condition (single)	Serious debilitating condition	Life-threatening or chronically debilitating condition	Serious diseases, (incl. difficult to treat diseases)	NA
Alternatives	None or Significant benefit to patient care vs alternatives	NA	None or significant benefit to patients	None or high effectiveness/safety vs alternatives	NA
Overseas Approval	Not previously refused for approval for safety	NA	NA	Sufficient clinical data or explanation of theoretical rationale for use in the target disease	NA
Performance	.NA.:	Propose to significantly modify evolution or enable remission of disease	NA	NA	Exempt from effectiveness evaluation

Applications







Value of Orphan Device Definitions

- Prevalence vs. incidence
- Scientific basis for cut-offs?
- How to define an orphan disease?
- Pragmatic approach





Do proposed definitions meet the unmet needs of cardiologists and cardiac surgeons?

Orphan devices and unmet medical needs

Patrick Myers, MD, FEBCTS, FESC

ESC Cardiovascular Round Table - 18 April 2024

